PFE logo Pfizer +
Pfizer
+

Pfizer (PFE) Business News

Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:00 AM | Wednesday | May 20, 2026 Business Wire

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

News Thumbnail
5:05 AM | Wednesday | May 20, 2026 Business Wire

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

News Thumbnail
8:00 AM | Monday | May 18, 2026 PRNewsWire

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

News Thumbnail
6:45 AM | Wednesday | May 13, 2026 Business Wire

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

News Thumbnail
7:00 AM | Tuesday | May 12, 2026 GlobeNewsWire

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

News Thumbnail
6:45 AM | Tuesday | May 5, 2026 Business Wire

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

News Thumbnail
6:45 AM | Wednesday | Apr 29, 2026 Business Wire

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

News Thumbnail
10:17 AM | Tuesday | Apr 28, 2026 Business Wire

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

News Thumbnail
6:59 AM | Friday | Apr 24, 2026 Business Wire

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

News Thumbnail
11:51 AM | Tuesday | Apr 21, 2026 Business Wire

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

News Thumbnail

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Business Wire

9:00 AM | Wednesday | May 20, 2026

news photo
Loading...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.

Read full article redirect
9:00 AM | Wednesday | May 20, 2026

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

Business Wire

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic collaboration with Pfizer Inc. to advance the development of Pfizer's oncology portfolio through a science‑driven and scaled research program designed to bring promising therapies to patients faster and closer to home. Central to the collaboration is SCRI's Accelero™, a next-generation clinic.

Read full article arrow
News Thumbnail
5:05 AM | Wednesday | May 20, 2026

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study (NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent pneumococcal conjugate vaccine candidate PF-07872412 (25vPnC) in infants compared to four doses of PREVNAR 20 at months 2, 4, 6 and 12-15. Based on the strong immune responses observed for all 25vPnC serotypes from Phase 2, compared to PREVNAR 20, Pfizer is confident that the req.

Read full article arrow
News Thumbnail
8:00 AM | Monday | May 18, 2026

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

PRNewsWire

10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29 - June 2 in Chicago, reinforcing Astellas' sustained commitment to improving outcomes for people living with cancer. The data will provide further insight into the durable efficacy of established treatment approaches, their use in clinical practice, and ongoing areas of research and development.

Read full article arrow
News Thumbnail
6:45 AM | Wednesday | May 13, 2026

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI® (marstacimab) to include patients 12 years of age and older weighing at least 35 kg with hemophilia A (congenital factor VIII [FVIII] deficiency) with FVIII inhibitors or hemophilia B (congenital factor IX [FIX] deficiency) with FIX inhibitors. HYMPAVZI offers a combination of superior bleed protection compared t.

Read full article arrow
News Thumbnail
7:00 AM | Tuesday | May 12, 2026

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

GlobeNewsWire

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE: PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, for the exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant).

Read full article arrow
News Thumbnail
6:45 AM | Tuesday | May 5, 2026

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results buildin.

Read full article arrow
News Thumbnail
6:45 AM | Wednesday | Apr 29, 2026

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression‑free survival (PFS), as assessed by blinded independent central review (BICR), v.

Read full article arrow
News Thumbnail
10:17 AM | Tuesday | Apr 28, 2026

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX® (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective U.
S. patent expiry date for VYNDAMAX to J.

Read full article arrow
News Thumbnail
6:59 AM | Friday | Apr 24, 2026

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Eliquis--Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company.

Read full article arrow
News Thumbnail
11:51 AM | Tuesday | Apr 21, 2026

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Business Wire

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, 2026, in Chicago. Data from more than 40 company-sponsored, investigator-sponsored and collaborative research abstracts, including three late-breaking sessions and eight oral and rapid oral presentations, will be shared. These data highlight Pfizer's leadership in establi.

Read full article arrow
News Thumbnail